GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes

The incretin-based therapies are represented by glucagon-like peptide 1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-IV inhibitors (DPP-IV). This new therapies have revolutionized the treatment of T2DM, intervening in a pathophysiological pathway not previously addressed. This chapter will review pathophysiology, mechanism of action, and indications for the use of GLP-1 RA.